BPC-157 vs VIP (Vasoactive Intestinal Peptide)

BPC-157 and VIP (Vasoactive Intestinal Peptide) are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157, a synthetic peptide composed of 15 amino acids, is derived from a naturally occurring protein in human gastric juice. Its molecular weight is approximately 1419.5 g/mol. Preclinical studies have highlighted its regenerative properties, particularly in the context of healing tendon, ligament, muscle, bone, nerve, gastrointestinal (GI) tract, and vascular injuries. Research indicates that BPC-157 may accelerate tendon and ligament repair, promote gut lining integrity, and mitigate NSAID-induced gastrointestinal damage. However, human clinical evidence remains sparse, with only three pilot studies published as of 2025, involving small sample sizes (knee pain n=16, interstitial cystitis n=12, IV safety n=2). The FDA categorizes BPC-157 as Category 2, reflecting significant safety concerns, and it is banned by WADA in competitive sports.

Vasoactive Intestinal Peptide (VIP) is a neuropeptide consisting of 28 amino acids, with a molecular weight of approximately 3326.8 g/mol. It is found throughout the central and peripheral nervous systems, as well as in the lungs and gastrointestinal tract. VIP is recognized for its potent vasodilatory and bronchodilatory effects, alongside its role as an immunomodulator. The synthetic derivative aviptadil (RLF-100) has been investigated for its potential in treating COVID-19-related acute respiratory distress syndrome (ARDS) and pulmonary arterial hypertension. Additionally, VIP is utilized in clinical settings for the diagnosis of VIPoma, a rare neuroendocrine tumor. Studies suggest that VIP may confer protective effects in lung injury and exhibit anti-inflammatory properties, although further research is necessary to fully understand its therapeutic potential.

BPC-157 and VIP target distinct yet occasionally overlapping research areas. BPC-157 is primarily investigated for its applications in injury recovery and gut health, particularly in enhancing the healing of musculoskeletal injuries and restoring the integrity of the gastrointestinal lining. In contrast, VIP is predominantly studied within the realms of pulmonary research, immunomodulation, and neuroscience. Its vasodilatory and neuroprotective properties position VIP as a candidate for addressing respiratory conditions and inflammatory diseases. While both peptides show promise in their respective fields, the differences in their mechanisms and applications highlight the need for targeted research strategies.

The safety profiles of BPC-157 and VIP differ significantly based on available evidence. BPC-157 has not undergone comprehensive randomized controlled trials in humans, leading to uncertainties regarding its safety. Preclinical studies indicate no observed toxic or lethal dose thresholds across various species at doses ranging from 6 mcg/kg to 20 mg/kg, with no teratogenic or genotoxic effects noted. However, the FDA's classification of BPC-157 as Category 2 underscores significant safety concerns, and a review is pending to assess its compounding eligibility. Conversely, VIP's very short plasma half-life (approximately 1-2 minutes) limits systemic effects, necessitating continuous infusion for therapeutic use. The primary dose-limiting adverse effect associated with VIP is hypotension, attributed to its potent vasodilatory action, with additional gastrointestinal side effects such as diarrhea and flushing observed at higher doses.